- Raw materials
- Others
- Slimming products
- Diethylpropion
Diethylpropion API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Diethylpropion | CAS No: 90-84-6 | GMP-certified suppliers
A medication that supports short-term adjunctive treatment of exogenous obesity by suppressing appetite to aid weight reduction alongside caloric restriction.
Therapeutic categories
Primary indications
- Used in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction
Product Snapshot
- Diethylpropion is available as oral tablets and extended-release capsules
- It is primarily indicated for short-term adjunctive use in weight management related to exogenous obesity
- The compound is approved for use in the US and Canada markets
Clinical Overview
Pharmacodynamically, diethylpropion acts as a stimulant promoting the release or maintenance of elevated levels of catecholamines—dopamine and norepinephrine—in the central nervous system. This catecholaminergic activity suppresses hunger signals by influencing neurotransmitter pathways involved in appetite regulation. It may also modulate leptin signaling, a hormone involved in satiety, and inhibit neuropeptide Y, a peptide that promotes eating, reduces energy expenditure, and favors fat storage. These combined effects contribute to reduced food intake and aid weight loss.
The pharmacokinetic profile of diethylpropion includes oral bioavailability supporting systemic exposure sufficient for central action. Metabolism pathways and elimination half-life data are consistent with other amphetamine analogues, facilitating dosing in clinical contexts focused on brief therapy durations.
Safety considerations include the potential for increased sympathetic activity, manifesting as tachycardia and hypertension, although diethylpropion is reported to produce less central nervous system disturbance and to be relatively safer for hypertensive patients compared to other drugs in this class. Caution is advised due to the risk of cardiovascular side effects and possible serotonergic interactions that could increase the risk of serotonin syndrome. The compound is regulated and approved for medical use in some jurisdictions but is also subject to illicit use.
In pharmaceutical development and API sourcing, quality control is essential to ensure purity and compliance with regulatory standards for amphetamine-related substances. Suppliers should provide documentation confirming the absence of impurities that could exacerbate safety risks. Robust batch testing and adherence to cGMP guidelines are critical for safe and effective diethylpropion API procurement.
Identification & chemistry
| Generic name | Diethylpropion |
|---|---|
| Molecule type | Small molecule |
| CAS | 90-84-6 |
| UNII | Q94YYU22B8 |
| DrugBank ID | DB00937 |
Pharmacology
| Summary | Diethylpropion is a sympathomimetic agent that promotes the release and sustains elevated levels of catecholamines, primarily dopamine and norepinephrine, by targeting sodium-dependent noradrenaline and dopamine transporters. This increase in catecholamines suppresses appetite by modulating central hunger pathways, including potential indirect effects on leptin signaling and inhibition of neuropeptide Y activity. It is utilized as an adjunctive treatment for short-term management of exogenous obesity through appetite suppression. |
|---|---|
| Mechanism of action | Diethylpropion is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. Diethylpropion (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that diethylpropion can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage. |
| Pharmacodynamics | Diethylpropion is a sympathomimetic stimulant drug marketed as an appetite suppressant. Chemically, it is the N,N-diethyl analog of cathinone. Its mechanism of action is similar to other appetite suppressants such as sibutramine, phentermine and dextroamphetamine. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Sodium-dependent noradrenaline transporter | Humans | inhibitor |
| Sodium-dependent dopamine transporter | Humans | inhibitor |
ADME / PK
| Absorption | Diethylpropion is rapidly absorbed from the GI tract after oral administration. |
|---|---|
| Half-life | Using a phosphorescence assay that is specific for basic compounds containing benzoyl group, the plasma half-life of the aminoketone metabolites is estimated to be between 4 to 6 hours. |
| Metabolism | Extensively metabolized through a complex pathway of biotransformation involving N-dealkylation and reduction. Many of these metabolites are biologically active and may participate in the therapeutic action of diethylpropion. |
| Route of elimination | Diethylpropion is rapidly absorbed from the GI tract after oral administration and is extensively metabolized through a complex pathway of biotransformation involving N-dealkylation and reduction. Diethylpropion and/or its active metabolites are believed to cross the blood-brain barrier and the placenta. Diethylpropion and its metabolites are excreted mainly by the kidney. |
Formulation & handling
- Diethylpropion is a small molecule suitable for oral administration in tablet or capsule form, including extended-release formulations.
- The compound exhibits moderate lipophilicity (LogP 2.7) and low to moderate water solubility, indicating formulation considerations for dissolution and bioavailability.
- Absorption of diethylpropion is not affected by food, allowing flexibility in dosing relative to meals.
Regulatory status
| Lifecycle | The API’s primary patents have expired in the US and Canada, resulting in a mature market characterized by the presence of multiple generic alternatives. Ongoing product availability in these regions reflects established therapeutic use and market competition. |
|---|
| Markets | US, Canada |
|---|
Supply Chain
| Supply chain summary | The diethylpropion supply landscape includes multiple originator and generic manufacturers, indicating an established production base with diverse sourcing options. Branded products are primarily present in the US and Canadian markets, with several controlled-release formulations available. Patent expirations have likely enabled existing generic competition, supported by numerous generic manufacturers active in the supply chain. |
|---|
Safety
| Toxicity | The reported oral LD<sub>50</sub> for mice is 600 mg/kg, for rats is 250 mg/kg and for dogs is 225 mg/kg. Manifestation of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states. |
|---|
- Handle with appropriate personal protective equipment to avoid ingestion or inhalation due to moderate acute toxicity
- May cause neurological symptoms upon acute overexposure, including tremors and altered mental status
- Store in a well-ventilated area away from incompatible substances to minimize risk of accidental exposure
Diethylpropion is a type of Slimming products
Slimming products are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that are specifically formulated to aid in weight loss and promote a healthy body mass index (BMI). These products are designed to target various aspects of weight management, including appetite control, metabolism enhancement, and fat burning.
One common type of slimming API is thermogenic agents. These substances work by increasing the body's core temperature, which stimulates the metabolism and promotes the burning of calories and fat. Popular thermogenic agents include caffeine, green tea extract, and capsaicin.
Another group of slimming APIs are appetite suppressants. These compounds work by reducing hunger pangs and cravings, helping individuals to consume fewer calories. Common appetite suppressants used in slimming products include glucomannan, a dietary fiber that expands in the stomach, and 5-HTP, a precursor to serotonin, a neurotransmitter that regulates appetite.
Additionally, lipase inhibitors are often included in slimming APIs. These substances inhibit the enzyme lipase, which is responsible for breaking down dietary fat. By blocking the action of lipase, these APIs prevent the absorption of dietary fat and reduce calorie intake.
Slimming products often combine multiple APIs to create synergistic effects and enhance weight loss results. It's important to note that slimming products should be used in conjunction with a balanced diet and regular exercise for optimal results. Prior to using any slimming APIs, it is recommended to consult with a healthcare professional to ensure their safe and effective use.
Diethylpropion (Slimming products), classified under Others
The others category refers to pharmaceutical APIs that do not fall under specific classifications such as antibiotics, antivirals, analgesics, or cardiovascular drugs. These APIs are diverse in nature and serve various therapeutic purposes, making them a crucial component of pharmaceutical formulations.
Pharmaceutical companies develop APIs in the others category to address specific medical conditions or target novel biological pathways. This category includes APIs used in oncology, neurology, immunology, and other specialized areas of medicine. The APIs in this category are often designed to interact with specific molecular targets or receptors, providing targeted therapeutic effects.
The development of APIs in the others category requires extensive research and testing to ensure their efficacy, safety, and compliance with regulatory standards. Pharmaceutical manufacturers employ advanced techniques such as chemical synthesis, biotechnology, and genetic engineering to produce these APIs.
Due to the broad range of applications and therapeutic uses, APIs in the others category contribute significantly to the advancement of medical treatments. Pharmaceutical companies constantly strive to innovate and discover new APIs within this category to address unmet medical needs and improve patient outcomes.
In conclusion, the others category of pharmaceutical APIs encompasses a diverse range of active ingredients used in drug formulation. These APIs play a crucial role in developing innovative therapies across various therapeutic areas, contributing to advancements in healthcare and patient well-being.
